---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-24-000062"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:12:01.750667+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "medium"
source: SEC EDGAR
---

# AEON Biopharma Phase 2 chronic migraine study misses primary and secondary endpoints

## Summary
- Phase 2 chronic migraine interim analysis did not achieve primary or secondary endpoints.
- End-of-Phase 2 meeting with FDA for episodic migraine resulted in preliminary alignment on Phase 3 design.
- Completed $15M private placement with Daewoong; second installment received April 2024.
- Seongsoo (Shawn) Park appointed to Board of Directors as Daewoong's representative.
- Company evaluating next-steps across late-stage clinical pipeline for ABP-450.

## SEC filing metadata
- accession: 0001837607-24-000062
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000062/0001837607-24-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000062/aeon-20240514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-24-000062
- JSON: https://secwatch.observer/filing/0001837607-24-000062.json
- Plain text: https://secwatch.observer/filing/0001837607-24-000062.txt

## Key facts
- Earnings Releases
  AEON Biopharma, Inc. reported financial results for the first quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Result: reported results
  source text: AEON Biopharma, Inc. (the “Company” or “AEON”) announced financial results for the fiscal quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000062/0001837607-24-000062-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.